TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06272370

Intervention type: OTHER
Group type: OTHER
Intervention: Asthma Symptom Monitoring online tools
Description: All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Steroids
Description: participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Steroids
Description: participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
Study: NCT06080035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cetyl Tranexamate Mesylate
Description: Topical product will be applied onto clean skin morning and night.
Study: NCT06574607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Educational Material for Decision-Making
Description: Using severe bleeding from abdominal-pelvic trauma as a scenario case, implementing decision-making teaching strategies to guide learners, and examining the intervention through this research

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Educational Material
Description: Teaching with scenario-based interactive materials without incorporating any teaching strategies
Study: NCT06575712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up
Description: A hybrid in-person and mHealth (mobile health) coping skills training and activity coaching intervention.
Study: NCT06272370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
Study: NCT05972070

Intervention type: DEVICE
Intervention: ROMTech Portable Connect
Description: The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
Study: NCT05001815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Description: The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
Study: NCT04693182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift schedule without quick returns
Description: The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
Study: NCT06410040

Intervention type: DRUG
Intervention: Lorlatinib
Description: lolatinib 100mg qd po
Study: NCT05001815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Description: Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
Study: NCT06345742

Intervention type: OTHER
Group type: OTHER
Intervention: No parental participation
Description: 1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Diaper care will be performed by the primary nurse.~4. Premature Infant Comfort Scale will be evaluated during and after the diaper care application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother participation
Description: 1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Mothers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Mothers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the mothers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application.
Study: NCT06575712

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Plus (UC+)
Description: Usual medical care plus videos delivering educational content via an app.
Study: NCT06345742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father participation
Description: 1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Fathers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Fathers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the fathers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application.
Study: NCT05195554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Description: Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
Study: NCT05660473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Anti-tumor alkaloids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Anthracycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Polyethylene glycol (PEG) conjugated to L-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Glucocorticoids
Study: NCT05847218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHN-001 (one tablet 750mg)
Description: Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
Study: NCT05660473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine antimetabolites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Glucocorticoids
Study: NCT05660473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antifolate antineoplastic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
Study: NCT05507073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Total Hip Replacement
Description: Implantation of a hip Device to alleviate pain and recover range of movement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Total Hip Replacement
Description: Robot assisted Implantation of a hip Device to alleviate pain and recover range of movement
Study: NCT05847218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHN-001 (750mg * 2 Tablets)
Description: Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHN-001 (750mg * 2 Tablets)
Description: Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
Study: NCT05827978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Description: Sterile suspension for injection
Study: NCT05474937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
Study: NCT05493553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement regimen
Description: The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and intermittent fasting regimen
Description: The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
Study: NCT05839769

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of median nerve with ultrasound
Description: ultrasound examination wrist

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of median nerve with ultrasound
Description: ultrasound examination wrist
Study: NCT05519254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysozyme
Description: Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lactoferrin + Lysozyme
Description: Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
Study: NCT04561479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alternative Exercises
Description: Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
Study: NCT05773859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XP-DC vaccinations
Description: Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
Study: NCT06057350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor removal
Description: Removal of incompletely removed early-stage colon cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor removal
Description: Removal of incompletely removed early-stage colon cancer
Study: NCT04656158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity involving exposure to nature: Therapeutic horticulture
Description: 2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity involving exposure to nature: Therapeutic horticulture
Description: 2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
Study: NCT06352853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision in Cesarean Section by Diathermy
Description: Skin incision by diathermy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision in Cesarean Section by Scalpel
Description: Skin incision by scalpel
Study: NCT06028230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444656 (KT-474)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444656 (KT-474)
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06465147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CAR19v3
Description: Single infusion of SCRI-CAR19v3
Study: NCT06171113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.
Study: NCT05698199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1001
Description: ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
Study: NCT05119231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Description: Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Pulmonary Vein Isolation
Description: Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
Study: NCT05513417

Intervention type: DEVICE
Intervention: Bloom Pod
Description: Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
Study: NCT05474937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Ketamine and Propofol
Description: Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Ketamine and Propofol
Description: Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
Study: NCT04608149

Intervention type: DEVICE
Intervention: Carpediem System
Description: Continuous renal replacement therapy
Study: NCT05472857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin 18.2 CAR-T
Description: treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
Study: NCT06198985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic balance exercise with tecnobody prokin 252 balance device
Description: Dynamic balance exercise with tecnobody prokin 252 balance device
Study: NCT04675060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139 capsules
Description: TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139 capsules
Description: TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
Study: NCT05491278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium for injection
Description: Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Study: NCT05578755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FutureU
Description: FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher.
Study: NCT06005441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: Provided as a ready for use injectable CBL-514 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-A1 Injection
Description: Provided as a ready for use injectable CBL-A1 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-A2 Injection
Description: Provided as a ready for use injectable CBL-A2 solution
Study: NCT06171113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.
Study: NCT06005441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (0.9% NaCl) placebo for injection